



Chinese SFDA Certificate awarded for AntiNuclear Antibody Microarray test from CapitalBio Corporation

Beijing, China. 2 April 2009. CapitalBio Corporation, China's leading developer of microarray diagnostic products and total analysis solutions announced the its AntiNuclear Antibody Test Array kit products for autoimmune disease testing had received a certificate for diagnostic use from the China State Food and Drug Administration (SFDA).

"The certification of the Antinuclear Antibody Array Test Kit for diagnostic use represents a new level in the quality of tests available to Chinese patients with systemic autoimmune diseases" said Jing Cheng, CEO of CapitalBio. "It is the first of a series of products the company plans to seek certification for general clinical diagnostic use in China. It is part of our current program to bring better and advanced diagnostics to China and to the emerging and developing lands of the world".

The microarray-based assay kit simultaneously tests for 8 different IgG antinuclear antibodies against SSA 52, SSA 60, SSB, Sm, RNP 68, Scl-70, Jo-1 and centromere B in patient serum. The microarray kits are supported with a full suite of instruments and dedicated software that provides a patient diagnosis and prognosis for autoimmune diseases automatically from the assay result. The kit can be used to aid the diagnosis of systemic autoimmune diseases such as systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD), Sjögren's syndrome (SS), systemic sclerosis (SSc), dermatomyositis (DM), polymyositis (PM) and CREST syndrome. These diseases are characterized by the presence of antinuclear antibodies (ANA) in the patient's blood which attack the individual's own tissues. This group of diseases affects some 2-3% of people world-wide.

ABOUT CAPITALBIO

CapitalBio Corporation is located in Beijing and is China's leading developer and marketer of diagnostic biochips, microarray related instruments and microarray services. The company, founded in 2000, currently has nearly 400 employees and is closely linked to the National Engineering Research Centre for Beijing Biochip Technology. Visit www.capitalbio.com for more information.

For more information about this announcement, please contact:
Ms. Chen REN
Assistant Director, Business Development Dept.
CapitalBio Corporation
Tel: +86-10-8071 5888 Ext. 8217
renchen2008@gmail.com